Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Adenocarcinoma
/ drug therapy
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacokinetics
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Drug Combinations
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Male
Maximum Tolerated Dose
Oxonic Acid
/ administration & dosage
Paclitaxel
/ administration & dosage
Prognosis
Tegafur
/ administration & dosage
Tissue Distribution
Combination chemotherapy
Non-small cell lung cancer
Paclitaxel
S1
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
08
06
2018
accepted:
10
08
2018
pubmed:
20
8
2018
medline:
6
2
2020
entrez:
20
8
2018
Statut:
ppublish
Résumé
This phase I study was aimed at determining the maximum tolerated dose (MTD) and recommended dose (RD) for oral S-1 plus paclitaxel combination therapy in elderly patients with non-small cell lung cancer (NSCLC). Chemotherapy-naïve patients (age, >70 years) with stage III/IV NSCLC were treated with paclitaxel intravenously at four dose levels (DLs), 60, 70, 80, and 90 mg/m
Identifiants
pubmed: 30121935
doi: 10.1007/s10637-018-0656-z
pii: 10.1007/s10637-018-0656-z
doi:
Substances chimiques
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-296Références
Respir Investig. 2018 Jan;56(1):80-86
pubmed: 29325686
Clin Cancer Res. 2001 Dec;7(12):3942-9
pubmed: 11751486
Br J Cancer. 2003 Mar 24;88(6):957-64
pubmed: 12644837
Lung Cancer. 2009 Oct;66(1):103-6
pubmed: 19193470
J Clin Oncol. 2015 Feb 20;33(6):575-81
pubmed: 25584004
J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
pubmed: 9890172
Int J Oncol. 2004 Dec;25(6):1531-6
pubmed: 15547687
Oncology. 1997 Jul-Aug;54(4):298-303
pubmed: 9216854
Chemotherapy. 2012;58(6):454-60
pubmed: 23392470
Br J Cancer. 2006 Dec 18;95(12):1642-7
pubmed: 17133268
Lung Cancer. 2008 Jun;60(3):381-6
pubmed: 18068853
J Clin Oncol. 2006 Aug 1;24(22):3657-63
pubmed: 16877734
Lung Cancer. 2010 Aug;69(2):213-7
pubmed: 20153912
Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9
pubmed: 18317763
Br J Cancer. 2001 Sep 28;85(7):939-43
pubmed: 11592762
Gan To Kagaku Ryoho. 2009 Mar;36(3):417-24
pubmed: 19295265
Clin Lung Cancer. 2008 Sep;9(5):280-4
pubmed: 18824450
J Natl Cancer Inst. 2003 Mar 5;95(5):362-72
pubmed: 12618501
Anticancer Res. 2008 May-Jun;28(3A):1593-602
pubmed: 18630517
Lancet. 2011 Sep 17;378(9796):1079-88
pubmed: 21831418